Summary
In the Covid-19-pandemic, the numbers of deceased do not consistently follow the number of new infections. The CFR mortality has declined in Germany from 5 % to 0.4 %. However, if we interpret the portion of positive tests as a positive rate, we find the positive rate and the numbers of deceased to run parallel with an offset of about 13 days. This has been observed worldwide in ten other countries and locally in Germany and North Rhine-Westphalia. In Germany the IFR mortality is about 29 per one million inhabitants, in the USA about 42, in Israel about 17, in the Netherlands 23, in Austria 27, in France 33, in Spain 36, in the UK 47 and Italy about 56 per million inhabitants. In Japan and South Korea the mortality rate is only about 3 per million inhabitants, with an offset of about 25 days.
The daily positive ratio, which is reported by state health authorities, allows to estimate the number of deaths (and seriously ill people) about 13 days ahead. This gives local hospitals more time for detailed planning. The daily positive rate may be interpreted as a “thermometer” of the respective country. The positive rate gives a much better picture of the state of the pandemic and should be reported by the media in addition to infection numbers. In official guidelines a 7-day-positive-rate is a much better guideline than the 7-day-incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB/oversight nesessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available on servers open to public
